ArticleClinical kidney journal2025
Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of obinutuzumab in refractory membranous nephropathy: a single-arm meta-analysis.Frontiers in immunology · 2026Pooled it
- Retrospective study of treatment effectiveness and remission predictors of obinutuzumab in primary membranous nephropathy.BMC nephrology · 2026Article
- Obinutuzumab versus rituximab in refractory membranous nephropathy: a single-center retrospective cohort study.BMC nephrology · 2026Article
- Pharmacokinetic profiling of rituximab in glomerular diseases: key determinants and implications for personalized therapy.Frontiers in pharmacology · 2026Review
- Earlier Hematuria Negative Conversion Was an Independent Predictor for Nephrotic Remission in Patients with Primary Membranous Nephropathy and Nephrotic Syndrome.American journal of nephrology · 2026Article
- Obinutuzumab in the treatment of idiopathic refractory membranous nephropathy: an observational case series.Frontiers in medicine · 2026Article
- Optimized RTX strategy plus structured glucocorticoid tapering for primary membranous nephropathy: a multicenter propensity score-matched cohort study.Frontiers in molecular biosciences · 2026Article
- Obinutuzumab after anti-rituximab antibody-associated treatment failure in membranous nephropathy: a case report.Frontiers in immunology · 2026Article
- Efficacy and safety of modified-dose obinutuzumab in the treatment of refractory membranous nephropathy.Frontiers in immunology · 2026Article
- Obinutuzumab as a Rescue and Maintenance Strategy in Children with Difficult-to-Treat Nephrotic Syndrome After Rituximab-Based Treatment Failure or Intolerance: A Preliminary Single-Center Real-World Retrospective Study.Drug design, development and therapy · 2026Article
- Treatment strategies for rituximab-resistant primary membranous nephropathy: from resistance mechanisms to emerging therapies.Frontiers in immunology · 2026Review
- CAR-T cell therapy in nephrology.Renal failure · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clinical experience with obinutuzumab in patients with rituximab-refractory phospholipase A2 receptor (PLA2R)-associated membranous nephropathy remains limited. This study aimed to evaluate the efficacy and safety of obinutuzumab in treating patients with rituximab-refractory PLA2R-associated membranous nephropathy. Methods: A single-center retrospective study was conducted on 20 patients with rituximab-refractory PLA2R-associated membranous nephropathy who received two doses of 1 g obinutuzumab, administered 2 weeks apart. At 6 months, patients with urinary protein levels exceeding 3.5 g/d received an additional dose of 1-2 g obinutuzumab. The primary clinical outcome was a composite measure of complete or partial remission during follow-up. Continuous secondary outcomes included 24-hour urinary protein, serum albumin, serum creatinine, serum anti-PLA2R levels, and CD19 B-cell counts at the time of obinutuzumab infusion, at 3 months, and at the last visit. Results: A total of 20 patients with clinical manifestations of nephrotic syndrome were included in this study, with a median follow-up period of 9 months. The mean age of the patients was 46.25 ± 13.05 years. At a median follow-up of 4.50 months (3.00-8.25 months) after obinutuzumab therapy, remission was achieved in 16 patients. Two patients (10%) achieved complete remission, while 14 (70%) attained partial remission. At baseline, 16 out of 20 patients tested positive for serum anti-PLA2R antibodies, and immunological remission was observed in 11 of these 16 patients during follow-up. All patients experienced B-lymphocyte depletion within 1 month after receiving obinutuzumab infusion and maintained this depletion at 3 months. B-lymphocyte reconstitution was noted in 4 out of 20 patients (20%) at 6 months. No patients experienced fatal adverse events. Conclusion: Obinutuzumab mainly induces short-term partial remissions in patients with rituximab-refractory primary membranous nephropathy, which may be related to the short follow-up period. However, this study demonstrates that obinutuzumab is an effective and safe treatment for rituximab-refractory PLA2R-associated membranous nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.